Eloxx Pharmaceuticals, Inc. (ELOX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.21 k

Shareholding (Dec 2023)

FII

3.86%

Held by 8 FIIs

DII

93.83%

Held by 2 DIIs

Promoter

0.00%

Who are in the management team of Eloxx Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Eloxx Pharmaceuticals, Inc. includes CEO Gregory Williams and Independent Chairman Tomer Kariv, along with several independent directors: Silvia Noiman, Zafrira Avnur, Martijn Kleijwegt, Ran Nussbaum, and Steven Rubin. This team oversees the company's governance and strategic direction.

Is Eloxx Pharmaceuticals, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Eloxx Pharmaceuticals, Inc. to determine if it is bullish or bearish.

Is Eloxx Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Eloxx Pharmaceuticals is fairly valued with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, making it more attractively priced compared to peers like Vertex Pharmaceuticals and Moderna.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.04

Return on Equity

101.61%

Price to Book

0.00

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2023)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

0.0%

1 Year

0.0%

2 Years

-99.99%

3 Years

-100.0%

4 Years

-100.0%

5 Years

-100.0%

Eloxx Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

6.95%

EBIT to Interest (avg)

-27.33

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.04

Sales to Capital Employed (avg)

Tax Ratio

0.37%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

19.76%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

EV to EBIT

-0.04

EV to EBITDA

-0.04

EV to Capital Employed

-0.04

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

101.61%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 9 Schemes (2.32%)

Foreign Institutions

Held by 8 Foreign Institutions (3.86%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Sep 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 52.00% vs 24.24% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.40",
          "val2": "-7.00",
          "chgp": "51.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.50",
          "chgp": "-60.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "0.10",
          "chgp": "200.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.60",
          "val2": "-7.50",
          "chgp": "52.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 45.88% vs -92.77% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-33.70",
          "val2": "-41.40",
          "chgp": "18.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.90",
          "val2": "1.30",
          "chgp": "46.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-23.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-36.10",
          "val2": "-66.70",
          "chgp": "45.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY

Sep'23

Sep'22

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-3.40

-7.00

51.43%

Interest

0.20

0.50

-60.00%

Exceptional Items

0.30

0.10

200.00%

Consolidate Net Profit

-3.60

-7.50

52.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Sep 2022

Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is 52.00% vs 24.24% in Sep 2022

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-33.70

-41.40

18.60%

Interest

1.90

1.30

46.15%

Exceptional Items

-0.00

-23.10

100.00%

Consolidate Net Profit

-36.10

-66.70

45.88%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 45.88% vs -92.77% in Dec 2021

All Annual Results

Company CV

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

Company Coordinates

Company Details

950 Winter St , WALTHAM MA : 02451-1424

Tel: 1 858 9090749

https://www.eloxxpharma.com/

Registrar Details

Eloxx Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

Who are in the management team of Eloxx Pharmaceuticals, Inc.?

Watch in Real-Time

Is Eloxx Pharmaceuticals, Inc. technically bullish or bearish?

Is Eloxx Pharmaceuticals, Inc. overvalued or undervalued?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY

Annual Results Snapshot (Consolidated) - Dec'22

About Eloxx Pharmaceuticals, Inc.

Company Coordinates